Status:
COMPLETED
Mechanisms of Rhinovirus Induced Asthma Exacerbations
Lead Sponsor:
Imperial College London
Conditions:
Rhinovirus Infection in Asthma
Eligibility:
All Genders
18-55 years
Phase:
NA
Brief Summary
We, the investigators, hypothesise that there are distinct gene profiles in rhinovirus-induced acute exacerbations of asthma. We further hypothesise that these changes in gene expression involve both ...
Eligibility Criteria
Inclusion
- Inclusion criteria for asthmatics:
- Age 18-55 years Doctor diagnosis of asthma Histamine PC20 \< 8 mg/mL Mild-to-moderate disease based on 2004 GINA criteria Treatment with either short-acting β-agonists (SABA) alone or with maintenance inhaled corticosteroids (daily dose between 200 μg and 1000 μg BDP equivalent) Worsening asthma symptoms with infection since last change in asthma therapy Atopic on skin testing (≥ 1 positive skin prick test on a panel of 10 aeroallergens)
- Inclusion criteria for healthy subjects:
- Age 18-55 years No history or clinical diagnosis of asthma or any other significant respiratory disease No history of allergic rhinitis or eczema Negative responses on skin prick testing (PC)20 \> 8 µg/mL Absence of significant systemic disease
- Exclusion criteria for asthmatics:
- History of severe asthma defined by GINA Smoking history over past 6 months or \> 5 pack year history Current symptoms of allergic rhinitis Current or previous history of significant respiratory disease (other than asthma) Any clinically relevant abnormality on screening or detected significant systemic disease Asthma exacerbation or viral illness within the previous 6 weeks Treatment with oral corticosteroids in the previous 3 months Current use of any nasal medication, anti-histamine, anti-leukotrienes, LABA, or anti-IgE therapy Presence of serum neutralising antibodies to rhinovirus-16 at screening Pregnant or breastfeeding women Contact with infants or elderly at home or at work
- Exclusion criteria for healthy subjects:
- History of atopy, asthma or any significant respiratory disease Smoking history over past 6 months or \> 5 pack year history Current symptoms of rhinitis Any clinically relevant abnormality on screening or detected significant systemic disease Viral illness within the previous 6 weeks Current use of any nasal medication or anti-histamine Presence of serum neutralising antibodies to rhinovirus-16 at screening Pregnant or breastfeeding women Contact with infants or elderly at home or at work
Exclusion
Key Trial Info
Start Date :
October 12 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2014
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT01159782
Start Date
October 12 2011
End Date
April 30 2014
Last Update
March 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Heart and Lung Institute
London, England, United Kingdom, W2 1PG